The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 3, 2009, Pages 185-196

  Giordano, Nicola ^a   Fioravanti, Antonella ^a   Papakostas, Panagiotis ^a   Montella, Antonio ^a   Giorgi, Giorgio ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

carryover effect; efficacy; glucosamine sulfate; knee osteoarthritis; tolerability

Indexed keywords

ACECLOFENAC; DICLOFENAC; GLUCOSAMINE SULFATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEARTBURN; HUMAN; INCIDENCE; JOINT STIFFNESS; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; MALE; MUSCULOSKELETAL PAIN; OUTPATIENT CARE; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; TREATMENT DURATION; VISUAL ANALOG SCALE;

EID: 67650222178     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.05.004     Document Type: Article

References (42)

1. Peat G., McCarney R., and Croft P. Knee pain and osteoarthritis in older adults: Review of community burden and current use of primary health care. Ann Rheum Dis. 60 (2001) 91-97
2. Jordan K.M., Arden N.K., Doherty M., et al., the Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 62 (2003) 1145-1155
3. Ofman J.J., Maclean C.H., Straus W.L., et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 29 (2002) 804-812
4. Huskisson E.C., Berry H., Gishen P., et al., the LINK Study Group (Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis). Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol. 22 (1995) 1941-1946
5. Bresalier R.S., Sandler R.S., Quan H., et al., the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N Engl J Med. 2006;355:221]. N Engl J Med. 352 (2005) 1092-1102
6. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ 332 (2006) 1302-1308
7. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 63 (2004) 901-907
8. Pincus T., Wang X., Chung C., et al. Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings [published correction appears in J Rheumatol. 2005;32:966]. J Rheumatol. 32 (2005) 533-539
9. Brandt K.D. Toward pharmacologic modification of joint damage in osteoarthritis. Ann Intern Med. 122 (1995) 874-875
10. Richette P., and Bardin T. Structure-modifying agents for osteoarthritis: An update. Joint Bone Spine 71 (2004) 18-23
11. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 45 (2006) 129-138
12. Altman R., Brandt K., Hochberg M., et al. Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society: Results from a workshop. Osteoarthritis Cartilage 4 (1996) 217-243
13. Group for the Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis. 55 (1996) 552-557
14. Noyszewski E.A., Wroblewski K., Dodge G.R., et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum. 44 (2001) 1089-1095
15. Bassleer C., Rovati L., and Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 6 (1998) 427-434
16. Varghese S., Theprungsirikul P., Sahani S., et al. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage 15 (2007) 59-68
17. Dodge G.R., and Jimenez S.A. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 11 (2003) 424-432
18. Conrozier T., Mathieu P., Piperno M., et al. Glucosamine sulfate significantly reduced cartilage destruction in a rabbit model of osteoarthritis. Arthritis Rheum. 41 Suppl (1998) 147
19. Largo R., Alvarez-Soria M.A., Díez-Ortego I., et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 11 (2003) 290-298
20. Chan P.S., Caron J.P., Rosa G.J., and Orth M.W. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage 13 (2005) 387-394
21. Rovati L.C., Poma A., Biavati G., et al. A multicenter, randomized, double-blind, parallel-group study to investigate efficacy and safety of oral glucosamine sulfate in osteoarthritis of the spine (1993), Rotthapharm, Milan, Italy
22. Noack W., Fisher M., Förster K.K., et al. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 2 (1994) 51-59
23. McAlindon T.E., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 283 (2000) 1469-1475
24. Towheed T.E., Maxwell L., Anastassiades T.P., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2 (2005) CD002946
25. Herrero-Beaumont G., Ivorra J.A., Del Carmen Trabado M., et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 56 (2007) 555-567
26. Reginster J.Y., Deroisy R., Rovati L.C., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
27. Pavelká K., Gatterová J., Olejarová M., et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162 (2002) 2113-2123
28. Clegg D.O., Reda D.J., Harris C.L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 354 (2006) 795-808
29. Rozendaal R.M., Koes B.W., van Osch G.J., et al. Effect of glucosamine sulfate on hip osteoarthri-tis: A randomized trial. Ann Intern Med. 148 (2008) 268-277
30. Altman R., Asch E., Bloch D., et al., the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum. 29 (1986) 1039-1049
31. Kellgren J.H., and Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 16 (1957) 494-502
32. Dougados M., Leclaire P., van der Heijde D., et al. Response criteria for clinical trials on osteoar-thritis of the knee and hip: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 8 (2000) 395-403
33. Bellamy N., Goldsmith C.H., Buchanan W.W., et al. Prior score availability: Observations using the WOMAC osteoarthritis index. Br J Rheumatol. 30 (1991) 150-151
34. Salaffi F., Leardini G., Canesi B., et al., the GOnorthrosis and Quality Of Life Assessment (GOQOLA). Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthritis Cartilage 11 (2003) 551-560
35. Rovati L.C. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: Current data and perspectives. Osteoarthritis Cartilage 5 (1997) 72
36. Persiani S., Roda E., Rovati L.C., et al. Glucosamine oral bioavailability and plasma pharmaco-kinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 13 (2005) 1041-1049
37. Persiani S., Rotini R., Trisolino G., et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 15 (2007) 764-772
38. Jackson C.G., Plaas A.H., Barnhill J.G., et al. The pharmacokinetics of oral glucosamine and chondroitin sulphate in human. Arthritis Rheum. 52 (2005) 4062-4063
39. Hoffer L.J., Kaplan L.N., Hamadeh M.J., et al. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 50 (2001) 767-770
40. Baron A.D., Zhu J.S., Zhu J.H., et al. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implication for glucose toxicity. J Clin Invest. 96 (1995) 2792-2801
41. Cannon G.W., Caldwell J.R., Holt P., et al., the Rofecoxib Phase III Protocol 035 Study Group. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoar-thritis of the knee and hip. Arthritis Rheum. 43 (2000) 978-987
42. Schnitzer T.J., Weaver A.L., Polis A.B., et al., the VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthri-tis of the knee: A combined analysis of the VACT studies. J Rheumatol. 32 (2005) 1093-1105